Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Astrazeneca Pharma India Ltd. Share Price
Day's Range
Day's Range
Low
₹8,352.00
High
₹8,499.50
Price Summary
| Previous Close | ₹8,391.00 |
|---|---|
| Day's Range | ₹8,352.00 - ₹8,499.50 |
| Open | ₹8,499.50 |
| 52 Week Range | ₹7,551.50 - ₹9,849.50 |
| Volume | 1,029 |
| Market Cap | ₹0.02 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 86.68 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.43 |
| Price/Earning (TTM) | 111.76 |
| TTM EPS (₹) | 75.01 |
| P/E Ratio | 185.90 |
| Book Value(₹) | 24.01 |
| PAT Margin (%) | 6.72 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 21.29 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 17162.9 | 4804.8 |
| Expenses | N/A | N/A |
| PBT | 1563.6 | 784.7 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1157.4 | 582.5 |
About Astrazeneca Pharma India Ltd.
| Founded | 1979 |
|---|---|
| NSE Symbol | ASTRAZEN |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,792.16 | 1,861.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,151.98 | 6,705.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,52,914.73 | 4,524.00 | 3,171.90 - 3,171.90 |
| Apollo Hospitals Enterprise Ltd. | 1,23,557.75 | 8,589.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,16,353.96 | 1,439.95 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,12,681.23 | 1,351.00 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,09,875.05 | 1,100.70 | 835.50 - 835.50 |
| Max Healthcare Institute Ltd. | 1,09,280.68 | 1,122.85 | 903.00 - 903.00 |
| Lupin Ltd. | 1,07,090.72 | 2,346.00 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,01,632.12 | 2,462.80 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
AstraZeneca Pharma India informs about resignation of senior management personnels
AstraZeneca Pharma India informs about updates
AstraZeneca Pharma India has informed that on June 10, 2026, the company has received permission from the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India to import for sale and distribution of Trastuzumab deruxtecan 100 mg/5mL vial lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu®) for an additional indication. Through this approval, Trastuzumab deruxtecan in combination with pertuzumab is indicated for the first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+ or ISH+) breast cancer. The receipt of this permission paves way for the marketing of Trastuzumab deruxtecan 100 mg/5mL vial lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu®) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.
The above information is a part of company’s filings submitted to BSE.
Vivo Bio Tech informs about closure of trading window
Mercury Laboratories informs about newspaper advertisement
Sudeep Pharma informs about closure of trading window
Pursuant to the Code of Conduct on Prevention of Insider Trading of the Company and SEBI (Prohibition of Insider Trading) Regulations, 2015, Sudeep Pharma has informed that the trading window for dealing in the securities of the Company shall be closed for designated persons from Wednesday, 1st July 2026 and shall remain closed till 48 hours after the declaration of the un-audited financial results of the Company for quarter ending on 30th June 2026 and other matters, if any. Accordingly, all Designated Persons and their immediate relatives, directly or indirectly, are prohibited to deal in the securities of the Company during this period. The date of the meeting of the Board of directors to approve the un-audited financial results of the company for the aforementioned quarter, shall be informed to the stock exchanges in due course.
The above information is a part of company’s filings submitted to BSE.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Astrazeneca Pharma India Ltd. is ₹8,391.00 as of 2026-06-25.
The market capitalisation of Astrazeneca Pharma India Ltd. is ₹20,956.62 as of 2026-06-25.
The 1-year return of Astrazeneca Pharma India Ltd. is -357.50% as of 2026-06-25.
The P/E ratio of Astrazeneca Pharma India Ltd. is 185.90 as of 2026-06-27.
The 52-week high and low of Astrazeneca Pharma India Ltd. are ₹9,849.50 and ₹7,551.50, respectively, as of 2026-06-25.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
